Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss the SUMMIT trial and how GLP-1 agonists may be a new pillar in the treatment for HFpEF and obesity. January 30, 2025 Uncategorized Disclosures: TBD Article Navigation Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson explore the question of what is the right weight reduction for each patient taking GLP-1 medications?
